Biological Markers for Multiple Sclerosis
Authors: Andreas Lutterotti; Thomas Berger; Markus Reindl
Source: Current Medicinal Chemistry, Volume 14, Number 18, August 2007 , pp. 1956-1965(10)
Publisher: Bentham Science Publishers
Abstract:Multiple sclerosis (MS) is the most common disabling neurological disease in young adults and is thought to result from an autoimmune attack against autoantigens within the myelin sheath. A characteristic feature of MS is the broad heterogeneity of clinical, histopathological and immunological phenotypes, which urges a more differentiated defining of patients by biological markers that reflect the underlying disease process and allow the prediction of disease courses and treatment responses. Here we review the current research on the identification of biomarkers for MS in cerebrospinal fluid and/or blood. We will focus on antibodies to myelin and non-myelin antigens, cells and soluble molecules of the immune system and the brain as biomarkers for 1) the diagnosis and prediction of clinical courses, 2) disease activity and 3) treatment response in MS.
Document Type: Research Article
Affiliations: Clinical Department of Neurology, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck,Austria.
Publication date: August 1, 2007
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.